Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma

Clin J Gastroenterol. 2021 Oct;14(5):1484-1490. doi: 10.1007/s12328-021-01470-y. Epub 2021 Jun 27.

Abstract

Use of lenvatinib, which has a high response rate in advanced hepatocellular carcinoma, sometimes results in tumor shrinkage and resectability of previously unresectable liver cancers. In Asia, including Japan, liver reserve, one of the determinants of resectability, is mainly determined by the indocyanine green (ICG) retention rate. Three patients with advanced liver cancer treated at our institution had very poor ICG retention rates during treatment with lenvatinib. Lenvatinib may reduce blood flow in both cancerous and non-cancerous regions by inhibiting vascular endothelial growth factor. Therefore, accurate determination of liver function likely requires withdrawal of this treatment several days before ICG retention testing.

Keywords: Conversion surgery; Hepatocellular carcinoma; Indocyanine green retention test; Lenvatinib.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Humans
  • Indocyanine Green
  • Liver Neoplasms* / drug therapy
  • Phenylurea Compounds
  • Quinolines
  • Vascular Endothelial Growth Factor A

Substances

  • Phenylurea Compounds
  • Quinolines
  • Vascular Endothelial Growth Factor A
  • lenvatinib
  • Indocyanine Green